Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study
{{output}}
Immunomodulatory therapeutics such as monoclonal antibodies (mAb) carry an inherent risk of undesired immune reactions. One such risk is cytokine release syndrome (CRS), a rapid systemic inflammatory response characterized by the secretion of pro-inflammatory ... ...
